Morgan Stanley Initiates Coverage On Karuna Therapeutics with Overweight Rating, Announces Price Target of $280
Portfolio Pulse from richadhand@benzinga.com
Morgan Stanley analyst Jeffrey Hung has initiated coverage on Karuna Therapeutics (NASDAQ:KRTX) with an Overweight rating and a price target of $280.
July 20, 2023 | 9:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Karuna Therapeutics has been given an Overweight rating by Morgan Stanley with a price target of $280.
The Overweight rating from Morgan Stanley indicates a positive outlook for Karuna Therapeutics. The high price target of $280 suggests that the analyst sees significant upside potential in the stock. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100